Phase II Study of BL-B01D1 With PD-1 Monoclonal Antibody for Treating Locally Advanced or Metastatic Non-small Cell Lung Cancer, Nasopharyngeal Carcinoma, and Other Solid Tumors

What this Trial Is About

Researchers are evaluating the effectiveness and safety of a combination treatment using BL-B01D1 and PD-1 Monoclonal Antibody in patients with locally advanced or metastatic non-small cell lung cancer, nasopharyngeal carcinoma, and other solid tumors. This phase II clinical trial aims to assess how well this combination works and its safety profile in these patient groups. Participants receive the study drugs as intravenous infusions in cycles lasting three weeks each. Those who show clinical benefit after the first cycle may continue receiving additional cycles. Treatment will stop if the disease progresses, if intolerable side effects occur, or for other reasons. The study focuses on evaluating the objective response rate and determining the recommended dose for phase II. During the trial, participants will be closely monitored with assessments up to approximately 24 months. Researchers will measure outcomes such as progression-free survival, disease control rate, duration of response, and any treatment-emergent adverse events. Participants will provide tumor tissue samples and undergo evaluations to track safety and effectiveness throughout the study period.

A Study of BL-B01D1+PD-1 Monoclonal Antibody in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer, Nasopharyngeal Carcinoma and Other Solid Tumors